cyrilzakka/clinical-trials huggingface dataset:
Intubation Time With Low Dose Rocuronium

The investigators hypothesized that increasing the cardiac output by use of atropine in children might result in a reduction of the intubation time needed to facilitate tracheal intubation.

The investigators hypothesized that increasing the cardiac output by use of atropine in children might result in a reduction of the intubation time needed to facilitate tracheal intubation. Therefore, the purpose of this study was to determine TimeEI with a low dose of esmeron (rocuronium) (0.3 mg.kg-1) for achievement of successful tracheal intubation conditions during intravenous (i.v.) anaesthesia using propofol and alfentanil in children and to determine whether administration of i.v. atropine (atropine sulphate) (10 μg.kg-1) during anaesthesia induction reduced these times.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I,
* Tonsillectomy with adenoidectomy

Exclusion Criteria:

* Patients with known allergy to the drugs used in this study,
* A history of reactive airway disease and asthma,
* A neuromuscular disorder, an anticipated difficult airway, and
* Crying children on arrival in the operating theatre
Perioperative Observation of the Sublingual Microcirculation With SDF

Does sublingual SDF-imaging results correlate with other haemodynamic parameters measured perioperatively and with postoperative morbidity/complications.


Eligibility Criteria:
Inclusion:

* major surgery \> 3h requiring arterial cannulation and central venous access

Exclusion Criteria:

* denied patient consent
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.


Eligibility Criteria:
Inclusion Criteria:

* Recipient of Single or Bilateral Lung Transplantation
* Informed consent
* Recipients who are able to receive Everolimus at week 3 after Lung Transplantation
* women of childbearing potential must have a negative pregnancy test within 48 hours of enrolment
* women of childbearing potential must use appropriate contraceptive method at enrolment, during the study and up to 8 weeks after the end of the study
* donor must not have relevant pulmonary diseases
* donor must have oxygen partial pressure higher than 300 mmHg at FiO 1.0 and positive end-expiratory pressure of 5 cm H2O.

Exclusion Criteria:

* systemic infection of the donor
* donor: signs or symptoms of aspiration
* donor: severe pulmonary injury or contusion
* donor: malignant neoplasm of the lung
* donor: HIV positive
* recipients who receive immunosuppressive agents not used in this protocol
* recipients who participated within 30 days before study start or are currently participating in another investigational drug trial
* HIV positive recipient
* systemic infection of the recipient
* recipients of combined/ multiple transplantations
* pregnancy of the recipient
* recipients with signs/ Symptoms of impaired wound healing of the pulmonary anastomoses
* recipients who are still on artificial respiration or who are not able to swallow tablets at week 3 after transplantation
Lipid Lowering Effect of Plant Stanol Ester in a Drinkable Non-dairy Product

The aim is to determine the effect of investigational products on serum LDL cholesterol.


Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent
* Mildly or moderately elevated plasma cholesterol levels (plasma total cholesterol 5.5-8.0 mmol/l)
* Plasma triglyceride levels ≤ 4.0 mmol/l
* Age 18-65 years

Exclusion Criteria:

* Intolerance to oats or other ingredients of the test products
* Severe obesity (BMI ≥ 32 kg/m2)
* Consumption of lipid/cholesterol lowering medication (e.g. ezetimibe, PCSK9 inhibitors, resins, fibrates) 1 month prior to the screening visit and throughout the study. Statin treatment is allowed at stable dose.
* Consumption of plant stanol or plant sterol containing food products or supplements or other foods or supplements such as beta-glucan enriched foods, red rice, berberine or any combination of these used for cholesterol lowering purpose 1 month prior the study entry (baseline blood sample)
* History of malignant diseases like cancer within five years prior to recruitment
* History of unstable coronary artery disease (myocardial infarction, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months
* Diagnosed type 1 or type 2 diabetes requiring medical treatment
* Celiac disease
* Medically prescribed diet/treatment for slimming or a special diet like very low calorie diet or use of prescribed an obesity drug (e.g. Orlistat, Victoza)
* Alcohol abuse (\> 4 portion/per day) or recreational drug abuse
* Pregnancy or planned pregnancy or lactating
* Clinically significant abnormalities in screening labs
* Participation in another clinical trial in the preceding 3 months
The Effect of Exercise Practices on Hyperactivity Levels in Children With Autism Spectrum Disorder

The aim of this study is to examine the effect of vestibular and proprioceptive exercise practices on the hyperactivity level in children with autism spectrum disorder.

The families of all children participating in the study will be informed and their written consent will be obtained. Vestibular and proprioceptive evaluation, hyperactivity evaluation and nystagmus evaluation will be applied to each child participating in the study twice, before and after treatment. Children will be divided into two groups: an exercise group and a control group, consisting of equal numbers of patients. A classical physical therapy program will be applied to both groups. In addition to the exercise group, a treatment program including vestibular and proprioceptive exercise training will be applied. The training program for both groups will be held in 40-minute sessions, 2 days a week for 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* children whose voluntary consent form is signed by their parents
* Children ages 6 to 10
* not using supplements
* not having undergone any surgical operation

Exclusion Criteria:

* children who have any obstacle to exercise
* They were determined as children who could not cooperate in the study.
Effect of Preoperative Curcumin in Breast Cancer Patients

Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients

Patients diagnosed with breast cancer will be supplemented with either curcumin or placebo for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients with operable breast cancer
* Life expectancy of at least 3 months
* Adequate organ function
* No allergy to curcumin
* Provides consent to participate in trial and adhere to the study protocol

Exclusion Criteria:

* Receiving concomitant radiotherapy, hormonal, immune therapy or other investigational drugs
* Uncontrolled concurrent illness
* Patient of anti platelet medications
* Pregnant / breast feeding
* Patients who are unable or unwilling to take curcumin, herbal remedies, or non-prescription medications
* Patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting profile
Writing Intervention With Adolescents and Young Adults With Cancer

Young people with cancer have difficult experiences and writing exercises may help improve their well-being. However, very few studies have examined how a creative writing activity might be useful for young people with cancer. In this pilot study, researchers at St. Jude Children's Research Hospital hope to explore whether teenagers and young adults with cancer want to participate in a writing exercise and whether they find it to be valuable.

Primary Objective

To assess the feasibility and acceptability of a writing-based narrative medicine intervention for adolescent and young adult patients with cancer.

Participants will be given the opportunity to write about their experiences with cancer, with support and guidance from an expert writer. Participants will meet briefly with the expert at the start of the exercise (15-30 minutes), and they can choose to meet 1-3 additional times with the expert over the next 2 months to receive further support if they wish.

After completing the writing exercise, participants will do an informal interview to share their thoughts about whether the experience of writing felt helpful or not. The post-intervention interview will occur at around 2 months after enrollment, +/- 1 month. Patients may participate in a second informal semi-structured interview 6 to 12 months after completing the first interview. Additionally, bereaved parents may participate in an informal interview on study.

Eligibility Criteria:
Inclusion Criteria:

* Aged 15-25
* Currently receiving cancer-directed therapy
* Active patient at St. Jude Children's Research Hospital
* Parent of a ChronCan participant who has passed away

Exclusion Criteria:

* Does not meet the inclusion criteria
* If the parents have not responded or not interviewed till December 31, 2025.
Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia

This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)

Community-acquired Pneumonia(CAP) remains a leading cause of death in both developing and developed countries. In the choice of antibacterial agents used to treat CAP, fluoroquinolones have received considerable attention because of their wide spectrum of bactericidal activity. TG-873870(Nemonoxacin), a non-fluorinated quinolone (NFQ), is a selective bacterial topoisomerase inhibitor. This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia (CAP) .

Eligibility Criteria:
Inclusion Criteria:

* If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)
* Must be a suitable candidate for oral antibiotic therapy and must be able to swallow capsules intact
* Must have a clinical diagnosis of CAP based on clinical evidence
* Must have a chest radiograph demonstrating new or persistent/progressive infiltrates
* Must be able to produce sputum

Exclusion Criteria:

* Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval
* Patients with CAP that, in the investigator's judgment, is severe enough to require hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy with ICU support
* Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease \[COPD\] is not exclusionary)
* Infection acquired in a hospital, nursing home, or other long-term care facility, or hospitalization for any reason within the previous 14 days
* Treatment with any antibiotics within the past 7 days prior to randomization, unless documents to be a treatment failure(72 hours treatment and not responding)
* Anticipation of the requirement for additional treatment with non-study antibacterials for any reason during the patient's participation in the study
* Treatment with chemotherapeutic agents or oncolytics during the 6 months prior to randomization or anticipated requirement for such agents during the course of the study
* Known or suspected CNS disorder that may predispose the patient to seizures or lower the seizure threshold
Liverpool Care Pathway for the Dying at Residential Care Homes

Liverpool Care Pathway for the dying patient (LCP) was developed to transfer the care practice from the hospice setting to the hospital setting in UK. LCP is a pathway with standardized registration method to monitor the care and its results. The primary aim is to study the effects of LCP on dying patients symptom burden and communication with close relatives and health care professionals.

All residential care homes in Skellefteå municipality are included in the study and randomized either to control or intervention group. During the baseline period the care is provided as usual. During the intervention period the LCP is used for patients for whom the dying phase is diagnosed in the intervention group. Usual care is performed for the control group. After death of a patient a close relative fill in a questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* nursing homes in Skellefteå municipality, Sweden

Exclusion Criteria:

-
Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty

Continuous lumbar plexus and femoral blocks have been demonstrated to provide effective postoperative analgesia of the lower extremity following total joint arthroplasty. The purpose of this study was to compare these two techniques when used with intravenous patient-controlled analgesia and the use of patient-controlled analgesia alone for postoperative pain management following unilateral total hip arthroplasty.

above may be applied

Eligibility Criteria:
Inclusion Criteria:

* 18-80 years old
* primary diagnosis of osteoarthritis

Exclusion Criteria:

* allergy to local anesthetics
* peripheral neuropathy
* opioid dependency
* dementia
* coagulopathy
Clinical Evaluation of Orion Lamina Cover in Patients Undergoing Lumbar Laminectomy With Instrumented Fusion

Laminectomy with internal fixation and osseofusion is a common surgery for treating degenerative spinal diseases. It removes excessive bone spurs and removes the lamina for decompression to relieve nerve compression, and then utilizes a spinal fixation system to stabilize the structure to relieve lower limb pain, paralysis, and other symptoms. However, the spinal cord that lacks lamina coverage after surgery is often compressed by scar tissue formation and hematoma, leading to postoperative back and lower limb pain. Therefore, this trial is divided into two groups, comparing the use of the cross connector of the ORION spinal system - the spinal lamina cover and the general spinal fixation system (without lamina cover). For participants undergoing laminectomy with internal fixation and osseofusion, after utilizing the spinal lamina cover of the ORION spinal system, whether the nerve compression caused by postoperative scar tissue formation and hematoma can be effectively reduced, and the pain in the back and lower limbs can be improved.


Eligibility Criteria:
Inclusion Criteria:

* Gender and age: females and males are at least 20 years old
* Who with degenerative lumbar spondylolisthesis in one or two consecutive segments from lumbar vertebra L1 to sacral vertebra S1, and have objective evidence of back pain and numbness radiating to the lower limbs.
* Clinical symptoms of degenerative lumbar spondylolisthesis, accompanied by objective symptoms of neurological deficit; spinal stenosis, neurogenic claudication or bilateral radiating pain.
* Have received at least 3 months of non-surgical treatment without effectiveness.
* Radiographic examination was consistent with clinical symptoms of degenerative spondylolisthesis or spinal stenosis.
* After diagnosis who needs laminectomy with internal fixation and osseofusion
* Able and willing to sign the consent form and answer the questionnaire.

Exclusion Criteria:

* Already had lumbar surgery at the same lumbar vertebra
* Physically health not well
* Probably pregnant
* Who suffering from malignant tumors or infections
* below 20 years old
* Unable and unwilling to answer the questionnaire and return to the hospital for treatment
* Unable to undergo MRI examination due to any reason, such as having a cardiac rhythm regulator, ferromagnetic implants, or claustrophobia.
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.


Eligibility Criteria:
Inclusion Criteria:

1. with non-valvular paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset).
2. Patient age 18-60 years.
3. Patients with Glomerular Filtration Rate (GFR) \>45 ml/min/1.73m2 (Cockcroft-Gault equation).
4. Patient with normal left atrium or dilated (diameter \<5 cm)

Exclusion Criteria:

1. Patients \< 18 yrs old.
2. Patients with valvular heart diseases (Moderate to severe MS, severe AS, Prosthetic heart valves).
3. Patients with left atrium \> 5cm.
4. Patients with glomerular Filtration Rate (GFR) \<45 ml/min/1.73m2 (Cockcroft-Gault equation).
5. Patient with ischemic heart disease (previous MI, UA, PCI or CABG).
6. Patient with previous ischemic stroke.
Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy

The purpose of this protocol is to study orbital structures in Graves´ Disease using multidetector computed tomography and color doppler imaging.

Some changes in orbital structures detected by imaging exams could predict severity of the ocular Graves´disease. Thus the study could be useful in improve medical management of patients with Graves´ Disease.

Morphometric analysis of orbital structures in Graves´ Orbitopathy using multidetector computed tomography scan and color doppler imaging:

Patients with Graves´ orbitopathy are evaluated by a complete ophthalmic examination.A prospective study with Multidetector CT scan and Color Doppler of these patients are made to develop parameters capable to predict Dysthyroid Optic Neuropathy (DON).

Eligibility Criteria:
Inclusion Criteria:

* Graves´Orbitopathy diagnosed based on previously reported criteria
* Age above 20 years
* Good cooperation for performing Visual Field test
* Spherical refraction within ± 5 D and cylinder correction within ± 3 D

Exclusion Criteria:

* Graves´Orbitopathy not diagnosed
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)


Eligibility Criteria:
Inclusion Criteria:

- Active choroidal neovascular AMD in at least one eye.

Exclusion Criteria:

* Retinal disease other than AMD that, in the investigator's opinion, would interfere with safety or study conduct.
* Choroidal neovascularization due to a cause other than AMD.
* In the study eye, media opacity that, in the investigator's opinion, would interfere with study conduct.
* Any disease or concomitant (or recent) medication expected to cause systemic immunosuppression.
* History of meningococcal meningitis in the past 10 years, or any history of recurrent meningitis.
* History of hospitalization for pneumococcal pneumonia within the past 3 years.
* History of serious systemic infection within the past 12 months.
* Any of the following treatments to the study eye within 7 days prior to study drug dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF inhibitor.

Other protocol-defined inclusion/exclusion criteria may apply
Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery.

All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.

This clinical assay will include 5 visits: the screening visit and four 9-hour postprandial metabolic sessions (A0, A1, B0 and C0) before and after surgery:

* initial visit: screening
* before surgery: 2 metabolic sessions A0 and A1 (without/with niacin) will be performed, in random order, at least one week interval.
* 12 days post surgery: 1 metabolic session B0 (without niacin)
* 1 year post surgery: 1 metabolic session C0 (without niacin)

Each metabolic visit will last 9 hours with:

* perfusion of stable tracers,
* ingestion of a liquid meal
* Positron-Emitting-Tomography (PET) acquisitions using radiopharmaceuticals such as \[18F\]-fluoro-6-thia-heptadecanoic acid (\[18F\]-FTHA) and \[11C\]-palmitate,
* MRI acquisitions.\[18F\]fluoro-6-thia-heptadecanoic acid (FTHA).

The niacin will be given during metabolic visits A1 as a regulator of lipids metabolism. During these visits, the subjects will ingest 150mg every half hour for 6 hours. Niacin will be used as a pharmacological suppressor of dietary fatty acid (DFA) spillover in order to determine the role played by this mechanism in the reduction of postprandial endogen glucose production (EGP) in T2D after bariatric surgery.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 to 65
* BMI 35 kg/m2
* Diagnosed T2D - according to Diabetes Canada diagnostics criteria.
* Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.
* Women with a negative serum pregnancy test.

Exclusion Criteria:

* Treatment with an oral contraceptive;
* Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects;
* Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions;
* Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension;
* Smoking or consumption of more than 2 alcoholic beverages per day;
* Any contraindication to MRI;
* A Diabetes Remission (DiaRem) score \>8 (low probability of T2D remission);
* Having participated to a research study with exposure to radiation in the last two years before the start of the study;
* Pregnant or breastfeeding women;
* Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners.
* Being allergic to eggs